In a major breakthrough for regenerative medicine, scientists have partially restored vision in a blind man using an emerging technique called optogenetics. The approach involved injecting the patient ...

The vision of a man who lost his sight because of retinitis pigmentosa (RP) has been partially restored with optogenetic therapy in the first reported case of functional recovery in a ...

DALLAS, Dec. 2, 2025 /PRNewswire/ -- Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor ...

Please provide your email address to receive an email when new articles are posted on . BARCELONA, Spain — In this Healio Video Perspective from the Euretina congress, Paulo-Eduardo Stanga, MD, ...

GS030 combines a gene therapy (GS030-DP) administered via a single intravitreal injection with a wearable optronic visual stimulation device (GS030-MD). Eligible patients in the first three cohorts ...

Please provide your email address to receive an email when new articles are posted on . The trial, which included 27 participants, met its safety and efficacy endpoints at 52 weeks and 76 weeks. The ...

Japan's Ministry of Health, Labour and Welfare (MHLW) grants MCO-010 Sakigake (Pioneering Regenerative Medical Product) and Orphan Drug designations, enabling an accelerated regulatory pathway for ...

PARIS--(BUSINESS WIRE)--GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal ...

DALLAS, Nov. 4, 2025 /PRNewswire/ -- Nanoscope Therapeutics Inc. announced today positive long-term safety results from its EXTEND study, a five-year follow-up of participants who received a single ...